Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain

Background Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence may increase the risk of relapse, leading to increased hospitalizations and emergency room (ER) visits. Long-acting injectables (LAIs) such as paliperidone palmitate have improved treatment...

Full description

Saved in:
Bibliographic Details
Published in:CNS drugs 2022-05, Vol.36 (5), p.517-527
Main Authors: Gutiérrez‐Rojas, Luis, Sánchez-Alonso, Sergio, García Dorado, Marta, López Rengel, Paola M.
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - therapeutic use
Antipsychotics
Aripiprazole
Aripiprazole - therapeutic use
Delayed-Action Preparations - therapeutic use
Electronic health records
Electronic medical records
Emergency medical care
Hospitalization
Hospitals
Humans
Medical records
Medicine
Medicine & Public Health
Mental disorders
Neurology
Neurosciences
Original
Original Research Article
Paliperidone Palmitate - therapeutic use
Palmitic acid
Patients
Pharmacotherapy
Pharmacy
Population
Primary care
Psychiatry
Psychopharmacology
Psychotropic drugs
Recurrence
Retrospective Studies
Schizophrenia
Schizophrenia - drug therapy
Spain
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence may increase the risk of relapse, leading to increased hospitalizations and emergency room (ER) visits. Long-acting injectables (LAIs) such as paliperidone palmitate have improved treatment adherence and therefore symptoms. However, real-world studies comparing 3-monthly LAI formulations with other LAIs and oral antipsychotics (OAs) are scarce. Objective The objective of this study was to investigate and evaluate the clinical effectiveness of paliperidone palmitate LAI monthly (PP1M; Xeplion ® ) and 3-monthly (PP3M; Trevicta ® ) formulations compared with the monthly LAI aripiprazole (AM; Abilify Maintena ® ) and OAs in Spain. Methods This was a retrospective, observational study including 2275 adult patients with schizophrenia in a Spanish population. Data from hospital, primary care, and pharmacy dispensation electronic medical records were obtained between January 2017 and February 2018. The main outcomes included psychiatric hospitalizations and ER visit rates, days on treatment, and treatment persistence. Results Patients receiving PP3M had a significantly lower mean hospitalization rate (0.00046 ± standard deviation [SD] 0.00181; p  
ISSN:1172-7047
1179-1934
DOI:10.1007/s40263-022-00917-1